Skip to main content
SpringerLink
Log in

Ophthalmic Complications of the Rheumatic Diseases and Anti-Rheumatic Drugs (in Elderly)

  • Chapter
  • First Online:
Rheumatic Disease in Geriatrics

  • 556 Accesses

Abstract

Ocular involvement in rheumatic diseases is common and can be realted either to the underlying condition or as a consequence of treatement. Changes to visual function tend to have an effect on patients daily activities, prompting them to seek immediate medical attention. As such, ocular complaints may be the presenting symptom in many cases and ophthalmologists the first physician to examine patients. Ocular findings can help in patient diagnosis, narrow the differential and offer a direct method for patient follow-up, demonstrating disease activity and evaluating response to treatment. Treatment for rheumatic diseases can also result in ocular complications and affect drug choices and patient management.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 69.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kyei S, Dzasimatu SK, Asiedu K, Ayerakwah PA. Association between dry eye symptoms and signs. J Curr Ophthalmol. 2018;30(4):321–5.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Onwubiko SN, Eze BI, Udeh NN, Arinze OC, Onwasigwe EN, Umeh RE. Dry eye disease: prevalence, distribution and determinants in a hospital-based population. Cont Lens Anterior Eye. 2014;37(3):157–61.

    Article  PubMed  Google Scholar 

  3. Asiedu K, Kyei S, Boampong F, Ocansey S. Symptomatic dry eye and its associated factors: a study of university undergraduate students in Ghana. Eye Contact Lens. 2017;43(4):262–6.

    Article  PubMed  Google Scholar 

  4. Cojocaru VM, Ciurtin C, Pop M, Tomi A, Grecu P. [Ophthalmological involvement in rheumatic disease]. Oftalmologia. 2006;50(2):56–61.

    Google Scholar 

  5. Craig JP, Nelson JD, Azar DT, Belmonte C, Bron AJ, Chauhan SK, et al. TFOS DEWS II report executive summary. Ocul Surf. 2017;15(4):802–12.

    Article  PubMed  Google Scholar 

  6. Milner MS, Beckman KA, Luchs JI, Allen QB, Awdeh RM, Berdahl J, et al. Dysfunctional tear syndrome: dry eye disease and associated tear film disorders – new strategies for diagnosis and treatment. Curr Opin Ophthalmol. 2017;27(Suppl 1):3–47.

    Article  PubMed  Google Scholar 

  7. Wan KH, Chen LJ, Young AL. Efficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysis. Ocul Surf. 2015;13(3):213–25.

    Article  PubMed  Google Scholar 

  8. Omega-3 fatty acid supplements do not improve symptoms of dry eye disease. Drug Ther Bull. 2018;56(12):144.

    Google Scholar 

  9. Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–16.

    Article  PubMed  Google Scholar 

  10. Tsirouki T, Dastiridou A, Symeonidis C, Tounakaki O, Brazitikou I, Kalogeropoulos C, et al. A focus on the epidemiology of uveitis. Ocul Immunol Inflamm. 2018;26(1):2–16.

    Article  PubMed  Google Scholar 

  11. Rodriguez A, Calonge M, Pedroza-Seres M, Akova YA, Messmer EM, D’Amico DJ, et al. Referral patterns of uveitis in a tertiary eye care center. Arch Ophthalmol. 1996;114(5):593–9.

    Article  CAS  PubMed  Google Scholar 

  12. Tugal-Tutkun I, Havrlikova K, Power WJ, Foster CS. Changing patterns in uveitis of childhood. Ophthalmology. 1996;103(3):375–83.

    Article  CAS  PubMed  Google Scholar 

  13. Sharma SM, Jackson D. Uveitis and spondyloarthropathies. Best Pract Res Clin Rheumatol. 2017;31(6):846–62.

    Article  PubMed  Google Scholar 

  14. Davatchi F, Chams-Davatchi C, Shams H, Shahram F, Nadji A, Akhlaghi M, et al. Behcet’s disease: epidemiology, clinical manifestations, and diagnosis. Expert Rev Clin Immunol. 2017;13(1):57–65.

    Article  CAS  PubMed  Google Scholar 

  15. Rosenbaum JT. Uveitis in spondyloarthritis including psoriatic arthritis, ankylosing spondylitis, and inflammatory bowel disease. Clin Rheumatol. 2015;34(6):999–1002.

    Article  PubMed  Google Scholar 

  16. Cunningham ET Jr, Smith JR, Tugal-Tutkun I, Rothova A, Zierhut M. Uveitis in children and adolescents. Ocul Immunol Inflamm. 2016;24(4):365–71.

    Article  PubMed  Google Scholar 

  17. Kezic JM, Davey MP, Glant TT, Rosenbaum JT, Rosenzweig HL. Interferon-gamma regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondylarthritis. Arthritis Rheum. 2012;64(3):762–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Robinson PC, Claushuis TA, Cortes A, Martin TM, Evans DM, Leo P, et al. Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol. 2015;67(1):140–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Tomkins-Netzer O, Talat L, Bar A, Lula A, Taylor SR, Joshi L, et al. Long-term clinical outcome and causes of vision loss in patients with uveitis. Ophthalmology. 2014;121(12):2387–92.

    Article  PubMed  Google Scholar 

  20. Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis. 2018;77(8):1107–17.

    PubMed  PubMed Central  Google Scholar 

  21. Suhler EB, Adan A, Brezin AP, Fortin E, Goto H, Jaffe GJ, et al. Safety and efficacy of adalimumab in patients with noninfectious uveitis in an ongoing open-label study: VISUAL III. Ophthalmology. 2018;125(7):1075–87.

    Article  PubMed  Google Scholar 

  22. Al-Janabi A, El Nokrashy A, Sharief L, Nagendran V, Lightman S, Tomkins-Netzer O. Long-term outcomes of treatment with biological agents in eyes with refractory, active, noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology. 2019;127(3):410–6.

    Article  PubMed  Google Scholar 

  23. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum. 2007;56(10):3248–52.

    Article  CAS  PubMed  Google Scholar 

  24. Wendling D, Paccou J, Berthelot JM, Flipo RM, Guillaume-Czitrom S, Prati C, et al. New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum. 2011;41(3):503–10.

    Article  PubMed  Google Scholar 

  25. Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121(3):785–96.e3.

    Article  PubMed  Google Scholar 

  26. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology. 2009;116(4):652–7.

    Article  PubMed  Google Scholar 

  27. Chang JR, Koo E, Agron E, Hallak J, Clemons T, Azar D, et al. Risk factors associated with incident cataracts and cataract surgery in the Age-Related Eye Disease Study (AREDS): AREDS report number 32. Ophthalmology. 2011;118(11):2113–9.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Asbell PA, Dualan I, Mindel J, Brocks D, Ahmad M, Epstein S. Age-related cataract. Lancet. 2005;365(9459):599–609.

    Article  PubMed  Google Scholar 

  29. Du DT, Wagoner A, Barone SB, Zinderman CE, Kelman JA, MaCurdy TE, et al. Incidence of endophthalmitis after corneal transplant or cataract surgery in a medicare population. Ophthalmology. 2014;121(1):290–8.

    Article  PubMed  Google Scholar 

  30. Francois J. Corticosteroid glaucoma. Ann Ophthalmol. 1977;9(9):1075–80.

    CAS  PubMed  Google Scholar 

  31. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363(9422):1711–20.

    Article  PubMed  Google Scholar 

  32. Martin TM, Smith JR, Rosenbaum JT. Anterior uveitis: current concepts of pathogenesis and interactions with the spondyloarthropathies. Curr Opin Rheumatol. 2002;14(4):337–41.

    Article  PubMed  Google Scholar 

  33. Bacchiega ABS, Balbi GGM, Ochtrop MLG, de Andrade FA, Levy RA, Baraliakos X. Ocular involvement in patients with spondyloarthritis. Rheumatology (Oxford). 2017;56(12):2060–7.

    Article  CAS  Google Scholar 

  34. Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67(7):955–9.

    Article  CAS  PubMed  Google Scholar 

  35. Mitulescu TC, Popescu C, Naie A, Predeteanu D, Popescu V, Alexandrescu C, et al. Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis. J Med Life. 2015;8(3):319–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Sepriano A, Rubio R, Ramiro S, Landewe R, van der Heijde D. Performance of the ASAS classification criteria for axial and peripheral spondyloarthritis: a systematic literature review and meta-analysis. Ann Rheum Dis. 2017;76(5):886–90.

    Article  PubMed  Google Scholar 

  37. Lyons JL, Rosenbaum JT. Uveitis associated with inflammatory bowel disease compared with uveitis associated with spondyloarthropathy. Arch Ophthalmol. 1997;115(1):61–4.

    Article  CAS  PubMed  Google Scholar 

  38. Paiva ES, Macaluso DC, Edwards A, Rosenbaum JT. Characterisation of uveitis in patients with psoriatic arthritis. Ann Rheum Dis. 2000;59(1):67–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Kujundzic M. [The role of biologic therapy in the treatment of extraintestinal manifestations and complications of inflammatory bowel disease]. Acta Med Croatica. 2013;67(2):195–201.

    Google Scholar 

  40. Zagora SL, McCluskey P. Ocular manifestations of seronegative spondyloarthropathies. Curr Opin Ophthalmol. 2014;25(6):495–501.

    Article  PubMed  Google Scholar 

  41. Jabs DA, Rosenbaum JT, Foster CS, Holland GN, Jaffe GJ, Louie JS, et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2000;130(4):492–513.

    Article  CAS  PubMed  Google Scholar 

  42. Gangaputra S, Newcomb CW, Liesegang TL, Kacmaz RO, Jabs DA, Levy-Clarke GA, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology. 2009;116(11):2188–98.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Guignard S, Gossec L, Salliot C, Ruyssen-Witrand A, Luc M, Duclos M, et al. Efficacy of tumour necrosis factor blockers in reducing uveitis flares in patients with spondylarthropathy: a retrospective study. Ann Rheum Dis. 2006;65(12):1631–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Pasadhika S, Rosenbaum JT. Update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biologics. 2014;8:67–81.

    PubMed  PubMed Central  Google Scholar 

  45. Yazgan S, Celik U, Isik M, Yesil NK, Baki AE, Sahin H, et al. Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis. Int Ophthalmol. 2017;37(1):139–45.

    Article  PubMed  Google Scholar 

  46. Rudwaleit M, Rodevand E, Holck P, Vanhoof J, Kron M, Kary S, et al. Adalimumab effectively reduces the rate of anterior uveitis flares in patients with active ankylosing spondylitis: results of a prospective open-label study. Ann Rheum Dis. 2009;68(5):696–701.

    Article  CAS  PubMed  Google Scholar 

  47. Acharya NR, Browne EN, Rao N, Mochizuki M, International Ocular Sarcoidosis Working Group. distinguishing features of ocular sarcoidosis in an international cohort of Uveitis patients. Ophthalmology. 2018;125(1):119–26.

    Article  PubMed  Google Scholar 

  48. Niederer RL, Al-Janabi A, Lightman SL, Tomkins-Netzer O. Serum angiotensin-converting enzyme has a high negative predictive value in the investigation for systemic sarcoidosis. Am J Ophthalmol. 2018;194:82–7.

    Article  CAS  PubMed  Google Scholar 

  49. Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA, et al. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103(10):1418–22.

    Article  PubMed  Google Scholar 

  50. Watson PG, Hayreh SS. Scleritis and episcleritis. Br J Ophthalmol. 1976;60(3):163–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Akpek EK, Thorne JE, Qazi FA, Do DV, Jabs DA. Evaluation of patients with scleritis for systemic disease. Ophthalmology. 2004;111(3):501–6.

    Article  PubMed  Google Scholar 

  52. Jabs DA, Mudun A, Dunn JP, Marsh MJ. Episcleritis and scleritis: clinical features and treatment results. Am J Ophthalmol. 2000;130(4):469–76.

    Article  CAS  PubMed  Google Scholar 

  53. Sainz de la Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS. Clinical characteristics of a large cohort of patients with scleritis and episcleritis. Ophthalmology. 2012;119(1):43–50.

    Article  PubMed  Google Scholar 

  54. Daniel Diaz J, Sobol EK, Gritz DC. Treatment and management of scleral disorders. Surv Ophthalmol. 2016;61(6):702–17.

    Article  CAS  PubMed  Google Scholar 

  55. Sen HN, Suhler EB, Al-Khatib SQ, Djalilian AR, Nussenblatt RB, Buggage RR. Mycophenolate mofetil for the treatment of scleritis. Ophthalmology. 2003;110(9):1750–5.

    Article  PubMed  Google Scholar 

  56. Sobrin L, Christen W, Foster CS. Mycophenolate mofetil after methotrexate failure or intolerance in the treatment of scleritis and uveitis. Ophthalmology. 2008;115(8):1416–21, 1421.e1.

    Article  PubMed  Google Scholar 

  57. Pujari SS, Kempen JH, Newcomb CW, Gangaputra S, Daniel E, Suhler EB, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology. 2010;117(2):356–65.

    Article  PubMed  Google Scholar 

  58. Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002;61(6):554–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Kobashi H, Kamiya K, Sambe T, Nakagawa R. Factors influencing subjective symptoms in dry eye disease. Int J Ophthalmol. 2018;11(12):1926–31.

    PubMed  PubMed Central  Google Scholar 

  60. Ramos-Casals M, Tzioufas AG, Stone JH, Siso A, Bosch X. Treatment of primary Sjogren syndrome: a systematic review. JAMA. 2010;304(4):452–60.

    Article  CAS  PubMed  Google Scholar 

  61. Ciurtin C, Ostas A, Cojocaru VM, Walsh SB, Isenberg DA. Advances in the treatment of ocular dryness associated with Sjogrens syndrome. Semin Arthritis Rheum. 2015;45(3):321–7.

    Article  CAS  PubMed  Google Scholar 

  62. Shih KC, Lun CN, Jhanji V, Thong BY, Tong L. Systematic review of randomized controlled trials in the treatment of dry eye disease in Sjogren syndrome. J Inflamm (Lond). 2017;14:26.

    Article  CAS  Google Scholar 

  63. Kassan SS, Moutsopoulos HM. Clinical manifestations and early diagnosis of Sjogren syndrome. Arch Intern Med. 2004;164(12):1275–84.

    Article  PubMed  Google Scholar 

  64. Shahram F, Maehlen MT, Akhlaghi M, Davatchi F, Liao YJ, Weyand CM. Geographical variations in ocular and extra-ocular manifestations in Behcet’s disease. Eur J Rheumatol. 2019;6(4):199–206.

    Article  PubMed  PubMed Central  Google Scholar 

  65. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behcet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–47.

    Article  Google Scholar 

  66. Tugal-Tutkun I, Gupta V, Cunningham ET. Differential diagnosis of behcet uveitis. Ocul Immunol Inflamm. 2013;21(5):337–50.

    Article  PubMed  Google Scholar 

  67. Figus M, Posarelli C, Albert TG, Talarico R, Nardi M. A clinical picture of the visual outcome in Adamantiades-Behcet’s disease. Biomed Res Int. 2015;2015:120519.

    PubMed  PubMed Central  Google Scholar 

  68. Amer R, Alsughayyar W, Almeida D. Pattern and causes of visual loss in Behcet’s uveitis: short-term and long-term outcomes. Graefes Arch Clin Exp Ophthalmol. 2017;255(7):1423–32.

    Article  PubMed  Google Scholar 

  69. Fabiani C, Vitale A, Emmi G, Vannozzi L, Lopalco G, Guerriero S, et al. Efficacy and safety of adalimumab in Behcet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol. 2017;36(1):183–9.

    Article  PubMed  Google Scholar 

  70. Keino H, Okada AA, Watanabe T, Nakayama M, Nakamura T. Efficacy of infliximab for early remission induction in refractory uveoretinitis associated with Behcet disease: a 2-year follow-up study. Ocul Immunol Inflamm. 2017;25(1):46–51.

    Article  CAS  PubMed  Google Scholar 

  71. Martin-Varillas JL, Calvo-Rio V, Beltran E, Sanchez-Burson J, Mesquida M, Adan A, et al. Successful optimization of adalimumab therapy in refractory uveitis due to Behcet’s disease. Ophthalmology. 2018;125(9):1444–51.

    Article  PubMed  Google Scholar 

  72. Atienza-Mateo B, Martin-Varillas JL, Calvo-Rio V, Demetrio-Pablo R, Beltran E, Sanchez-Burson J, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behcet’s disease: national multicenter study of 177 cases. Arthritis Rheumatol. 2019;71(12):2081–9.

    Article  CAS  PubMed  Google Scholar 

  73. Diwo E, Gueudry J, Saadoun D, Weschler B, LeHoang P, Bodaghi B. Long-term efficacy of interferon in severe uveitis associated with Behcet disease. Ocul Immunol Inflamm. 2017;25(1):76–84.

    Article  CAS  PubMed  Google Scholar 

  74. Lightman S, Taylor SR, Bunce C, Longhurst H, Lynn W, Moots R, et al. Pegylated interferon-alpha-2b reduces corticosteroid requirement in patients with Behcet’s disease with upregulation of circulating regulatory T cells and reduction of Th17. Ann Rheum Dis. 2015;74(6):1138–44.

    Article  CAS  PubMed  Google Scholar 

  75. Palejwala NV, Walia HS, Yeh S. Ocular manifestations of systemic lupus erythematosus: a review of the literature. Autoimmune Dis. 2012;2012:290898.

    PubMed  PubMed Central  Google Scholar 

  76. Dammacco R, Procaccio P, Racanelli V, Vacca A, Dammacco F. Ocular involvement in systemic lupus erythematosus: the experience of two tertiary referral centers. Ocul Immunol Inflamm. 2018;26(8):1154–65.

    Article  CAS  PubMed  Google Scholar 

  77. Peponis V, Kyttaris VC, Tyradellis C, Vergados I, Sitaras NM. Ocular manifestations of systemic lupus erythematosus: a clinical review. Lupus. 2006;15(1):3–12.

    Article  CAS  PubMed  Google Scholar 

  78. Jabs DA, Miller NR, Newman SA, Johnson MA, Stevens MB. Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol. 1986;104(4):564–8.

    Article  CAS  PubMed  Google Scholar 

  79. Stafford-Brady FJ, Urowitz MB, Gladman DD, Easterbrook M. Lupus retinopathy. Patterns, associations, and prognosis. Arthritis Rheum. 1988;31(9):1105–10.

    Article  CAS  PubMed  Google Scholar 

  80. Nguyen QD, Uy HS, Akpek EK, Harper SL, Zacks DN, Foster CS. Choroidopathy of systemic lupus erythematosus. Lupus. 2000;9(4):288–98.

    Article  CAS  PubMed  Google Scholar 

  81. Silpa-archa S, Lee JJ, Foster CS. Ocular manifestations in systemic lupus erythematosus. Br J Ophthalmol. 2016;100(1):135–41.

    Article  PubMed  Google Scholar 

  82. Read RW, Chong LP, Rao NA. Occlusive retinal vasculitis associated with systemic lupus erythematosus. Arch Ophthalmol. 2000;118(4):588–9.

    Article  CAS  PubMed  Google Scholar 

  83. Au A, O’Day J. Review of severe vaso-occlusive retinopathy in systemic lupus erythematosus and the antiphospholipid syndrome: associations, visual outcomes, complications and treatment. Clin Exp Ophthalmol. 2004;32(1):87–100.

    Article  PubMed  Google Scholar 

  84. Jabs DA. Immunosuppression for the uveitides. Ophthalmology. 2018;125(2):193–202.

    Article  PubMed  Google Scholar 

  85. Tomkins-Netzer O, Talat L, Ismetova F, Samy A, Lightman S. Immunomodulatory therapy in uveitis. Dev Ophthalmol. 2016;55:265–75.

    Article  PubMed  Google Scholar 

  86. Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, et al. Association between long-lasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317(19):1993–2005.

    Google Scholar 

  87. Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, et al. Corticosteroid-related adverse events systematically increase with corticosteroid dose in noninfectious intermediate, posterior, or panuveitis: post hoc analyses from the VISUAL-1 and VISUAL-2 trials. Ophthalmology. 2017;124(12):1799–807.

    Article  PubMed  Google Scholar 

  88. Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Louis TA, Sugar EA, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment trial. Ophthalmology. 2011;118(10):1916–26.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Friedman DS, Holbrook JT, Ansari H, Alexander J, Burke A, Reed SB, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology. 2013;120(8):1571–9.

    Article  PubMed  PubMed Central  Google Scholar 

  90. Thorne JE, Sugar EA, Holbrook JT, Burke AE, Altaweel MM, Vitale AT, et al. Periocular triamcinolone vs. intravitreal triamcinolone vs. intravitreal dexamethasone implant for the treatment of uveitic macular edema: the PeriOcular vs. INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2018;126(2):283–95.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Tomkins-Netzer O, Taylor SR, Bar A, Lula A, Yaganti S, Talat L, et al. Treatment with repeat dexamethasone implants results in long-term disease control in eyes with noninfectious uveitis. Ophthalmology. 2014;121(8):1649–54.

    Article  PubMed  Google Scholar 

  92. Marmor MF. Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol. 2012;130(4):461–9.

    Article  CAS  PubMed  Google Scholar 

  93. Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453–60.

    Article  PubMed  Google Scholar 

  94. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF, American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123(6):1386–94.

    Article  PubMed  Google Scholar 

  95. Ophthalmologists RCo. Hydroxychloroquine and chloroquine retinopathy: recommendations on screening 2018 [10 August 2019]. Available from: https://www.rcophth.ac.uk/wp-content/uploads/2018/07/Hydroxychloroquine-and-Chloroquine-Retinopathy-Screening-Guideline-Recommendations.pdf.

  96. Vallet H, Seve P, Biard L, Baptiste Fraison J, Bielefeld P, Perard L, et al. Infliximab versus adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French Uveitis Network. Arthritis Rheumatol. 2016;68(6):1522–30.

    Article  CAS  PubMed  Google Scholar 

  97. Deitch I, Amer R, Tomkins-Netzer O, Habot-Wilner Z, Friling R, Neumann R, et al. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies. Graefes Arch Clin Exp Ophthalmol. 2018;256(4):801–8.

    Article  CAS  PubMed  Google Scholar 

  98. Fabiani C, Sota J, Rigante D, Vitale A, Emmi G, Lopalco G, et al. Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol. 2018;37(10):2805–9.

    Article  PubMed  Google Scholar 

  99. Lejoyeux R, Diwo E, Vallet H, Saadoun D, Tezenas du Montcel S, Bodaghi B, et al. INFLIXIMAB and ADALIMUMAB in uveitic macular edema. Ocul Immunol Inflamm. 2018;26(7):991–6.

    Article  CAS  PubMed  Google Scholar 

  100. Calvo-Rio V, de la Hera D, Beltran-Catalan E, Blanco R, Hernandez M, Martinez-Costa L, et al. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review. Clin Exp Rheumatol. 2014;32(4 Suppl 84):S54–7.

    PubMed  Google Scholar 

  101. Tappeiner C, Mesquida M, Adan A, Anton J, Ramanan AV, Carreno E, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2016;43(12):2183–8.

    Article  CAS  PubMed  Google Scholar 

  102. Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, et al. Primary (Month-6) outcomes of the STOP-uveitis study: evaluating the safety, tolerability, and efficacy of tocilizumab in patients with noninfectious uveitis. Am J Ophthalmol. 2017;183:71–80.

    Article  CAS  PubMed  Google Scholar 

  103. Atienza-Mateo B, Calvo-Rio V, Beltran E, Martinez-Costa L, Valls-Pascual E, Hernandez-Garfella M, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet’s disease: multicentre retrospective study. Rheumatology (Oxford). 2018;57(5):856–64.

    Article  CAS  Google Scholar 

  104. Ramanan AV, Dick AD, Jones AP, Guly C, Hardwick B, Hickey H, et al. A phase II trial protocol of tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial). BMC Rheumatol. 2018;2:4.

    Article  PubMed  PubMed Central  Google Scholar 

  105. Heissigerova J, Callanan D, de Smet MD, Srivastava SK, Karkanova M, Garcia-Garcia O, et al. Efficacy and safety of sarilumab for the treatment of posterior segment noninfectious uveitis (SARIL-NIU): the phase 2 SATURN study. Ophthalmology. 2019;126(3):428–37.

    Article  PubMed  Google Scholar 

  106. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013;120(4):777–87.

    Article  PubMed  Google Scholar 

  107. Letko E, Yeh S, Foster CS, Pleyer U, Brigell M, Grosskreutz CL, et al. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy. Ophthalmology. 2015;122(5):939–48.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Moorfields Eye Hospital, London, UK

    Xia Ni Wu & Lazha Sharief

  2. Ophthalmology Department, Wolfson Medical Center, Holon, Israel

    Asaf Bar

  3. Ophthalmology Department, Bnai Zion Medical Center, Institute of Technology, Technion, Haifa, Israel

    Karin Hershcu

  4. Ophthalmology Department, Kings College Hospital, London, UK

    Lazha Sharief

  5. Ophthalmology Department, Lady Davis Carmel Medical Center, Ruth and Bruch Rappaport Faculty of Medicine, Technion – Israel Institute of Technology, Haifa, Israel

    Oren Tomkins-Netzer

  6. Institute of Ophthalmology, University College London, London, UK

    Oren Tomkins-Netzer

Authors
  1. Xia Ni Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asaf Bar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Karin Hershcu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lazha Sharief
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Oren Tomkins-Netzer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oren Tomkins-Netzer .

Editor information

Editors and Affiliations

  1. Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel

    Gleb Slobodin

  2. Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel

    Yehuda Shoenfeld

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wu, X.N., Bar, A., Hershcu, K., Sharief, L., Tomkins-Netzer, O. (2020). Ophthalmic Complications of the Rheumatic Diseases and Anti-Rheumatic Drugs (in Elderly). In: Slobodin, G., Shoenfeld, Y. (eds) Rheumatic Disease in Geriatrics . Springer, Cham. https://doi.org/10.1007/978-3-030-44234-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-44234-7_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-44233-0

  • Online ISBN: 978-3-030-44234-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation